Clinical laboratory evaluation of Invader® chemistry and hybrid capture for detection of high-risk human papillomavirus in liquid-based cytology specimens

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 3, 2011, Pages 230-235

  Munson, Erik ^a,b   Du Chateau, Brian K ^c   Bellerose, Bronya ^c   Czarnecka, Jolanta ^a   Griep, Judy ^a  

^a Wheaton Franciscan Laboratory   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c Converge Diagnostic Services ^*  (United States)

Author keywords

Human papillomavirus; Hybrid capture; Invader

Indexed keywords

GENOMIC DNA; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA CONTENT; DNA EXTRACTION; FALSE POSITIVE RESULT; HYBRID CAPTURE; INTERMETHOD COMPARISON; INVADER CHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

CERVIX UTERI; FEMALE; HUMANS; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS;

EID: 80053918678     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.07.004     Document Type: Article

References (23)

1. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 1995, 87:796-802.
2. Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., Schiffman M. Human papillomavirus genotype specificity of Hybrid Capture 2. J. Clin. Microbiol. 2008, 46:2595-2604.
3. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., WHO International Agency for Research on Cancer Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005, 6:204.
4. Davey D.D., Neal M.H., Wilbur D.C., Colgan T.J., Styer P.E., Mody D.R. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology. Arch. Pathol. Lab. Med. 2004, 128:1224-1229.
5. Einstein M.H., Martens M.G., Garcia F.A.R., Ferris D.G., Mitchell A.L., Day S.P., Olson M.C. Clinical validation of the Cervista® HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol. Oncol. 2010, 118:116-122.
6. Ginocchio C.C., Barth D., Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the Digene HPV Hybrid Capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol. 2008, 46:1641-1646.
7. Johnson L.R., Starkey C.R., Palmer J., Taylor J., Stout S., Holt S., Hendren R., Bock B., Waibel E., Tyree G., Miller G.C. A comparison of two methods to determine the presence of high-risk HPV cervical infections. Am. J. Clin. Pathol. 2008, 130:401-408.
8. Kjaer S., Høgdall E., Frederiksen K., Munk C., van den Brule A., Svare E., Meijer C., Lorincz A., Iftner T. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006, 66:10630-10636.
9. Meijer C.J., Snijders P.J., Castle P.E. Clinical utility of HPV genotyping. Gynecol. Oncol. 2006, 103:12-17.
10. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.
11. Ortiz M., Torres M., Muñoz L., Fernández-García E., Canals J., Cabornero A.I., Aguilar E., Ballesteros J., del Amo J., García-Sáiz A. Oncogenic human papillomavirus (HPV) type distribution and HPV type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk. J. Clin. Microbiol. 2006, 44:1428-1434.
12. Poljak M., Marin I.J., Seme K., Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 2002, 25(suppl 3):S89-S97.
13. Schutzbank T.E., Jarvis C., Kahmann N., Lopez K., Weimer M., Yount A. Detection of high-risk papillomavirus DNA with commercial Invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J. Clin. Microbiol. 2007, 45:4067-4069.
14. Seme K., Fujs K., Kocjan B.J., Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA test using polymerase chain reaction and genotyping. J. Virol. Methods 2006, 134:252-256.
15. Sherman M.E., Schiffman M., Cox J.T. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J. Natl. Cancer Inst. 2002, 94:102-107.
16. Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 2001, 93:293-299. ALTS Study Group.
17. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
18. Wheeler C., Hunt W.C., Schiffman M., Castle P.E. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J. Infect. Dis. 2006, 194:1291-1298.
19. Wong A.K., Chan R.C., Nichols W.S., Bose S. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay. J. Clin. Microbiol. 2008, 46:869-875.
20. Wright T.C., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J., American Society for Colposcopy and Cervical-Pathology Sponsored Consensus Conference 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287:2120-2129.
21. Wright T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., Hatch K., Noller K.L., Roach N., Runowicz C., Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 2004, 103:304-309.
22. Wright T.C. HPV DNA testing for cervical cancer screening. FIGO 6th annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 2006, 95:S239-S246.
23. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference (2007): 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 2006, 197:346-355.